Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mucin 1 (MUC1) is a highly glycosylated type I transmembrane mucin protein overexpressed and aberrantly glycosylated in many epithelial cancers. It functions as a tumor-associated antigen presented to CD8+ cytotoxic T lymphocytes (CTLs) via MHC-I, leading to tumor cell lysis. MUC1 expressed on activated T cells also functions as a negative regulator of T cell proliferation. MUC1 is a target for cancer immunotherapy and vaccines.
CTL activation via presentation of MUC1-derived peptides on MHC-I; Modulation of T cell activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucin 1 (MUC1).